It refers to the time from random grouping to death from any cause (for the subjects who are lost to follow-up before death, the last follow-up time is usually used as the time of death), which is the most reliable index to evaluate the efficacy of anti-tumor drugs.
The difficulty of OS implementation and analysis lies in the long-term follow-up of a large sample of people, and it is easily disturbed by the potential effects of subsequent drugs, so as to analyze the survival time.
Extended information 2065438+On August 23rd, 2006, The Lancet published the results of a large-scale randomized controlled phase III clinical trial of recurrent and metastatic nasopharyngeal carcinoma jointly conducted by Tension Team of Cancer Hospital affiliated to Sun Yat-sen University and 22 domestic hospitals.
362 patients with recurrent or metastatic nasopharyngeal carcinoma were randomly divided into gemcitabine combined with cisplatin treatment group or fluorouracil combined with cisplatin control group according to 1∶ 1. The results showed that the overall survival time of gemcitabine group was 29.65438 0 months, which was 9 months longer than that of fluorouracil group.
The same review in The Lancet pointed out that this research result is expected to be written into international guidelines as a standard first-line chemotherapy regimen for recurrent or metastatic nasopharyngeal carcinoma.
A multicenter, randomized controlled phase III clinical study of gemcitabine combined with cisplatin in the treatment of recurrent or metastatic nasopharyngeal carcinoma conducted by Professor Zhang Li's team extended the median progression-free survival time of patients with recurrent or metastatic nasopharyngeal carcinoma from 5.6 months to 7 months, and the total survival time from 20. 1 month to 29. 1 month.
This study provides strong evidence for standardizing the chemotherapy scheme of recurrent or metastatic nasopharyngeal carcinoma, and gives Chinese medical workers the right to speak in related fields. On the other hand, considering the high cost of malignant tumor treatment, while the curative effect is improved, the cost-effectiveness of the new chemotherapy scheme is still worth further study.
Baidu encyclopedia-OS
People's Daily Online -20 16 Top Ten Medical Science and Technology News in China